These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36720762)

  • 1. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
    Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
    J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
    Rosenberg T; Yeo KK; Mauguen A; Alexandrescu S; Prabhu SP; Tsai JW; Malinowski S; Joshirao M; Parikh K; Farouk Sait S; Rosenblum MK; Benhamida JK; Michaiel G; Tran HN; Dahiya S; Kachurak K; Friedman GK; Krystal JI; Huang MA; Margol AS; Wright KD; Aguilera D; MacDonald TJ; Chi SN; Karajannis MA
    Neuro Oncol; 2022 Nov; 24(11):1964-1975. PubMed ID: 35397478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
    Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
    Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
    J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
    Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
    J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
    Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
    J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of high-grade glioma in children and adolescents.
    MacDonald TJ; Aguilera D; Kramm CM
    Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
    Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
    Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
    Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
    Mackay A; Burford A; Molinari V; Jones DTW; Izquierdo E; Brouwer-Visser J; Giangaspero F; Haberler C; Pietsch T; Jacques TS; Figarella-Branger D; Rodriguez D; Morgan PS; Raman P; Waanders AJ; Resnick AC; Massimino M; Garrè ML; Smith H; Capper D; Pfister SM; Würdinger T; Tam R; Garcia J; Thakur MD; Vassal G; Grill J; Jaspan T; Varlet P; Jones C
    Cancer Cell; 2018 May; 33(5):829-842.e5. PubMed ID: 29763623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
    Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
    Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
    Guerra-García P; Marshall LV; Cockle JV; Ramachandran PV; Saran FH; Jones C; Carceller F
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28011. PubMed ID: 31617673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.
    Gnekow AK; Kandels D; Tilburg CV; Azizi AA; Opocher E; Stokland T; Driever PH; Schouten-van Meeteren AYN; Thomale UW; Schuhmann MU; Czech T; Goodden JR; Warmuth-Metz M; Bison B; Avula S; Kortmann RD; Timmermann B; Pietsch T; Witt O
    Klin Padiatr; 2019 May; 231(3):107-135. PubMed ID: 31108561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.